SEATTLE, April 3, 2008 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that it has entered into a definitive agreement with an institutional investor to sell 8.0 million shares of its common stock and warrants to purchase up to 8.0 million shares of its common stock for gross proceeds of approximately $47 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering. The investor has agreed to purchase the shares of common stock and warrants to purchase common stock at a negotiated purchase price of $5.92 per share and a warrant exercise price of $20.00 per share. For the common stock purchased, this represents a 17% premium to the closing bid price of the common stock on April 2, 2008. The warrants will be exercisable at any time on or after October 8, 2008 and prior to the seventh anniversary of the closing of the transaction. The closing bid price of the common stock on the Nasdaq Global Market on April 2, 2008 was $5.06 per share. Lazard Capital Markets LLC served as sole placement agent for the offering.
The securities described above are being offered by Dendreon pursuant
to registration statements previously filed and declared effective by the
Securities and Exchange Commission (the "SEC"). The transaction is expected
to close on or about April 8, 2008, subject to customary closing
conditions. We intend to use the net proceeds from the sale of the shares
to fund our commercialization activities for Provenge(R) (sipuleucel-T),
including the investment in specialized technology systems; to fund
clinical trials for PROVENGE and our other product candidates; to fund our
other research and preclinical development activities for our active
|SOURCE Dendreon Corporation|
Copyright©2008 PR Newswire.
All rights reserved